BioXcel Therapeutics - Chapter 11 Plan Terms
BioXcel’s liquidating Chapter 11 plan is premised on the sale of substantially all of its assets to a Teva affiliate for $57.5 million in cash plus up to $67.5 million in contingent milestone payments linked to FDA approval of its pending at-home IGALMI sNDA and future sales. Net of reserves for administrative and priority claims, professional fees, and the wind-down, proceeds are applied first to the up to $77.25 million DIP provided by Oaktree- and Qatar Investment Authority-affiliated lenders, which rolled up $58.25 million of their approximately $111.8 million in prepetition term loan principal, and then to their remaining prepetition secured claims, which are projected to recover 84.4%. General unsecured creditors will look primarily to a reserve funded with 30% of litigation recoveries, capped at $1 million, for a projected recovery of 0% to 2.9%.
Plan Terms
Overview
- BioXcel Therapeutics, Inc. and two affiliates are seeking confirmation of a liquidating Chapter 11 plan, set out in a second amended combined disclosure statement and plan dated Oct. 20, 2026. The plan carries out the sale of substantially all of their assets to Teva Pharmaceuticals International GmbH, an affiliate of Teva Pharmaceutical Industries Ltd., for $57.5 million in cash at closing plus up to $67.5 million in contingent milestone payments. The milestone payments depend on the outcome of BioXcel's pending supplemental new drug application, or sNDA, to expand its agitation drug IGALMI to at-home use, and on future commercial performance.
- No competing qualified bids were received by the Oct. 9, 2026, bid deadline, and on Oct. 13 the debtors cancelled the auction and named Teva the successful bidder.
- Cash and milestone rights go first to the DIP lenders and then to the prepetition secured lenders. The lenders are funds affiliated with Oaktree Capital Management and the Qatar Investment Authority. They held approximately $111.8 million in prepetition term loan principal at filing and provided the $77.25 million DIP, of which $58.25 million is a roll-up. Oaktree Fund Administration, LLC is agent under both facilities.
- All other assets, including the debtors' retained causes of action, vest in a liquidation trust. The main source of recovery for general unsecured creditors is a GUC recovery reserve funded with 30% of litigation proceeds and capped at $1 million. The prepetition lenders negotiated the reserve with the board's Strategic Process Committee.
- No official unsecured creditors' committee has been formed. The U.S. Trustee's Sept. 10, 2026, statement that no committee had been appointed cited an insufficient response to its outreach.
- The debtors project recoveries of 84.4% for prepetition secured claims, 0% to 2.9% for general unsecured claims, and zero for intercompany claims, subordinated claims, section 510(b) claims and equity. The filing states that the estimates exclude recoveries on retained causes of action, though the 2.9% high end for general unsecured claims assumes a $1 million contribution to the GUC recovery reserve, which is funded only from those recoveries. Because the plan liquidates the debtors, it provides no discharge under section 1141(d)(3).
Teva Sale
- Price: $57.5 million in cash at closing, up to $67.5 million in contingent milestone payments, and the assumption of certain liabilities, including cure costs of up to $2.5 million. The terms are set out in an asset purchase agreement, or APA, dated Aug. 26, 2026.
- Deposit: $5.75 million, held by an escrow agent.
- Bid protections: a break-up fee of $1.15 million, rising to $5 million if the FDA approves the sNDA before the APA is terminated, plus reimbursement of reasonable and documented expenses of up to $575,000. The court approved the bid protections, the bidding procedures and Teva's APA by order entered Sept. 28, 2026 [Docket No. 179].
- Qualified bids were due Oct. 9, 2026, at 12:00 p.m. (ET). Each had to offer cash at closing above $57.5 million plus the bid protections, which the debtors put at $1.725 million (3% of the upfront payment), plus a $1,000,000 initial minimum overbid increment, together with contingent payment rights at least equal in value to Teva's. None was received. On Oct. 13, 2026, the debtors filed a notice [Docket No. 232] cancelling the auction and naming Teva the successful bidder.
- The combined document anticipates entry of the sale order on Oct. 21, 2026. The DIP facility requires the sale to close by Oct. 26, 2026. The APA's outside date is Oct. 30, 2026, unless the parties agree to extend it. Closing the sale under the APA and the sale order is a condition to the plan's effective date.
- Teva used its right to exclude the immuno-oncology programs BXCL701 and BXCL702, which sit in debtor OnkosXcel Therapeutics, LLC. The debtors will try to sell those assets before the effective date, transfer them to the liquidation trust, or abandon them if keeping them is not likely to be worth the cost. Any disposition before the effective date needs the consent of the DIP agent and prepetition agent, not to be unreasonably withheld.
- Teva is not buying, and is paying nothing for, the artificial intelligence platform BioXcel has used. The platform still belongs to non-debtor affiliate BioXcel LLC (formerly BioXcel Corporation), which originally formed BioXcel as a subsidiary, contributed BXCL501, BXCL701, BXCL502 and BXCL702 to it in 2017, and is party to a shared services agreement with BioXcel for administrative and other services; there has been no development activity with BioXcel LLC since Dec. 31, 2024. The debtors attribute no value to their own internal AI tools, citing reduced investment in and use of them since at least the quarter ended Sept. 30, 2025.
Milestone Payments
- Development milestones: only one payment is due, and its size depends on when the FDA approves the sNDA:
- $67.5 million if approval is received on or before Nov. 21, 2026
- $55 million if approval is received after Nov. 21, 2026, and on or before Feb. 28, 2027
- $20 million if approval is received after Feb. 28, 2027, and on or before May 31, 2027
- $5 million if approval is received after May 31, 2027, and on or before Nov. 30, 2027
- The FDA's Nov. 14, 2026, target action date on the sNDA comes before the Nov. 21 cutoff for the top payment.
- Commercial milestones: if approval is not received by Feb. 28, 2027, the APA provides for two payments, and none is due if either of the two highest development payments is earned:
- $10 million when annual net sales of the milestone product first reach $250 million or more, on or before Dec. 31, 2035
- An additional $10 million when annual net sales first reach $500 million or more, by the same date
- The debtors caution that recoveries on the milestone rights depend on whether and when the sNDA is approved, the amount and timing of net sales, and Teva's performance under the APA.
DIP and Other Unclassified Claims
- Distributable cash under the plan is all of the debtors' cash on the effective date, including sale proceeds and any milestone proceeds received before then. From that, the plan deducts funding for the wind-down reserve, the professional fee reserve and a reserve for allowed administrative, priority tax and priority non-tax claims, each in an amount reasonably acceptable to the DIP agent and prepetition agent. Distributable cash is paid directly to the agents rather than through the liquidation trust.
- DIP claims are paid in cash on the effective date to the extent not already paid from sale proceeds or distributable cash under the DIP order, unless the holders agree otherwise. If the DIP claims are not paid in full in cash at the sale closing, the debtors will assign contingent payment rights to the DIP agent on the effective date, free and clear. Their value will be agreed by the debtors and the prepetition agent with the DIP holders' consent, or set by the court, and credited against the DIP claims. DIP recoveries are capped at the allowed claim. DIP holders receive nothing from the GUC recovery reserve until general unsecured claims other than deficiency claims are paid in full.
- Distributable value may fall short of paying both the DIP claims and the administrative, priority tax and priority non-tax claims that must be paid for confirmation on the effective date. In that case, consistent with the DIP order, the DIP agent and DIP lenders are deemed to waive administrative expense priority on the roll-up portion of the DIP claims in the amount of the shortfall, up to the outstanding roll-up principal. The waiver does not affect the DIP claims themselves, the DIP liens or the superpriority status of the new money loans.
- Restructuring expenses, meaning the fees and expenses of the lender professionals under the DIP order, are paid in full in cash before and on the effective date. No fee applications, itemized time records or court review are required. Estimates are due at least three business days before the expected effective date, and the trustee pays any amounts invoiced later.
- After the effective date, the trustee also pays in full, without court approval, the reasonable and documented fees of the DIP agent, DIP lenders, prepetition agent and prepetition lenders, including their professionals. These cover implementing the plan; overseeing the wind-down, the trust and the trustee; exercising consent and consultation rights; and enforcing their rights under the DIP order and loan documents. Their costs of cancelling the loan documents are paid without reducing their recoveries.
- Administrative claims are paid in full in cash on the later of the effective date and 30 days after allowance. Priority tax claims receive, at the debtors' or trustee's discretion, the same treatment or installment payments with interest over up to five years from the petition date.
Treatment of Claims and Interests
- Class 1, priority non-tax claims (unimpaired, deemed to accept): cash in full on the later of the effective date and 30 days after allowance; projected recovery 100%.
- Class 2, other secured claims (unimpaired, deemed to accept): at the debtors' or trustee's option, cash equal to the value of the claim or return of the collateral; projected recovery 100%.
- Class 3, prepetition secured claims (impaired, entitled to vote): once the DIP claims are satisfied, holders receive:
- a pro rata share of the distributable cash remaining on the effective date
- any contingent payment rights not assigned to the DIP agent, valued as agreed by the debtors and the prepetition agent with the holders' consent, or as set by the court
- a pro rata share of remaining liquidation trust assets other than the GUC recovery reserve, from which Class 3 receives nothing until Class 4 is paid in full
- Class 3 recoveries are capped at the allowed claim, and any unpaid balance becomes a deficiency claim in Class 4; projected recovery 84.4%.
- Class 4, general unsecured claims (impaired, entitled to vote): a pro rata share of the GUC recovery reserve, paid out as litigation proceeds come in, and of any trust assets left after unclassified claims and Classes 1 through 3. The debtors estimate the lenders' deficiency claims at approximately $8.4 million. Those claims share in the remaining trust assets but receive nothing from the GUC recovery reserve until all other Class 4 claims are paid in full, and they shrink dollar for dollar with each distribution on the DIP and prepetition secured claims. Projected recovery is 0% to 2.9%: the high end assumes a $1 million contribution to the reserve for claims other than deficiency claims, and the low end assumes no contribution.
- Class 5, intercompany claims (unimpaired or impaired; deemed to accept or reject): adjusted, reinstated or discharged without distribution; projected recovery 0%.
- Class 6, subordinated claims (impaired, deemed to reject): a pro rata share of trust assets left after unclassified claims and Classes 1 through 4; projected recovery 0%.
- Class 7, section 510(b) claims (impaired, deemed to reject): a pro rata share of trust assets left after unclassified claims, Classes 1 through 4 and Class 6, ranking equally with Class 8, with the split set by a calculation method to be filed with the plan supplement; projected recovery 0%.
- Class 8, interests (impaired, deemed to reject): cancelled, ranking equally with Class 7 in the same remaining trust assets under the plan supplement's calculation method; projected recovery 0%. If trust assets remain after Classes 1 through 4 and Class 6 are paid in full and the trustee finds a distribution to Classes 7 and 8 is not economically feasible, the trustee may donate the funds to one or more charities not affiliated with the trustee or the trust.
- Classes 6 through 8, and possibly Class 5, are deemed to reject the plan, so the debtors will seek confirmation under section 1129(b).
GUC Recovery Reserve and Retained Causes of Action
- Size: 30% of any proceeds the liquidation trust receives from pursuing, settling or compromising retained causes of action, capped at $1 million.
- The prepetition lenders and the Strategic Process Committee negotiated the reserve. It gives general unsecured creditors a recovery from litigation proceeds that would otherwise be subject to the DIP liens on substantially all assets and/or the prepetition lenders' lien on the debtors' three lawsuits over the compromised TRANQUILITY Phase 3 trial.
- The reserve is available to Class 4 claims other than deficiency claims whether or not the DIP and prepetition secured claims are paid in full. Outside the reserve, Class 4 receives no litigation proceeds until those senior claims are paid in full.
- Retained causes of action vest in the trust. They include claims against any party that owed a debtor a fiduciary, contractual or statutory duty, committed a tort against a debtor, or received an avoidable transfer. They exclude claims released under the plan or the DIP order and claims sold to Teva. A list will be filed with the plan supplement. The trustee alone may pursue and settle these claims, without court approval.
- The debtors caution that if the wind-down reserve cannot fund the litigation, the trustee may need outside financing or contingency counsel, which would be paid from proceeds before any distributions to creditors.
Key Dates
- The debtors are seeking conditional approval of the combined document for solicitation purposes. The court will consider final approval of whether it contains adequate information at the combined hearing.
- The remaining case calendar is as follows:
- Oct. 23, 2026: voting record date; general claims bar date at 5:00 p.m. (prevailing Eastern Time)
- Oct. 26, 2026: DIP milestone for closing the Teva sale
- Oct. 30, 2026: APA outside date, which the parties may extend by agreement
- Nov. 14, 2026: deadline to challenge the final DIP order's stipulations, admissions, waivers and releases in favor of the prepetition agent and lenders; FDA target action date on the sNDA
- Nov. 20, 2026, at 4:00 p.m. (ET): voting deadline
- Nov. 21, 2026: last date for sNDA approval to earn the $67.5 million development milestone
- Nov. 23, 2026, at 4:00 p.m. (ET): deadline to object to final approval of the disclosure statement and to confirmation
- Dec. 3, 2026, at 11:00 a.m. (ET): combined hearing on final disclosure statement approval and confirmation
- Feb. 23, 2027, at 5:00 p.m. (prevailing Eastern Time): bar date for government claims
- The plan supplement, including the liquidation trust agreement and the trustee's identity, is due at least seven days before the voting deadline. The plan supplement will also contain:
- the list of retained causes of action
- the contract assumption schedule
- the Class 7 and Class 8 calculation method
- any exceptions to the debtor release and the exculpation
- The debtors may amend the plan supplement through the effective date. Material changes need the consent of both agents, not to be unreasonably withheld.
Pending Matters
- The final DIP order sets Nov. 14, 2026, as the deadline to challenge the debtors' stipulations, admissions, waivers and releases in favor of the prepetition agent and lenders. These include the debtors' stipulation that the prepetition liens are valid, enforceable and properly prioritized, on collateral that includes certain retained causes of action.
- Before filing, BioXcel agreed to a proposed settlement of the Hills shareholder class action in the District of Connecticut, providing for a $9.75 million payment funded by the debtors' insurers and subject to final approval by the district court. After the debtors filed a suggestion of bankruptcy on Aug. 31, 2026, the plaintiffs kept seeking final approval in district court, which led to an order to show cause requiring BioXcel to set out, by Oct. 7, a timeline for seeking bankruptcy court approval of the settlement. The plaintiffs moved on Sept. 24 for stay relief to let the final approval hearing proceed in district court, and that motion remains pending; the debtors moved on Sept. 28 to enforce the automatic stay, and on Oct. 6 the bankruptcy court entered an order confirming and enforcing the stay, halting further proceedings against the debtors in Hills until the stay expires or the court orders otherwise. The debtors expect to file a motion to approve the settlement so the district court can grant final approval.
DIP Financing
- Size: up to $77.25 million, provided as a multi-draw senior secured superpriority priming term loan under sections 364(c) and 364(d). It consists of $19 million in new money term loans and a $58.25 million cashless, dollar-for-dollar roll-up of prepetition secured obligations, rolled up pro rata as the new money is funded. The court entered the final DIP order at Docket No. 149, and the DIP credit agreement is dated Aug. 31, 2026.
- Rate: 13% per year on both tranches, paid in cash on the new money loans and in kind on the roll-up loans.
- Exit fee: 4.0% of the total principal amount of all DIP loans repaid.
- Maturity: the earliest of five months from closing, closing of a court-approved sale, the effective date of a confirmed plan, or certain events of default.
- Use of proceeds: working capital and general corporate purposes, case administration costs, and pursuing and closing a value-maximizing sale, all under the final DIP order and the budget approved by the required DIP lenders.
- Security: first-priority senior priming liens on substantially all of the debtors' property, including retained causes of action and their proceeds, plus superpriority claims. The prepetition secured parties receive adequate protection liens and superpriority claims.
- Milestones are measured from the petition date. Each can be extended with the consent of the DIP agent acting at the direction of the DIP agent and prepetition agent, or by court order:
- 30 days: entry of the bidding procedures order and the final DIP order
- 50 days: auction, if necessary
- 60 days: entry of the sale order and closing of the sale; entry of the solicitation procedures order
- 105 days: entry of the confirmation order
- 115 days: occurrence of the effective date
- The prepetition lenders would not consent to a priming facility from a third party but were willing to fund the debtors themselves. While evaluating that offer, MTS asked 11 other lenders for unsecured, junior secured or senior secured financing, the last conditioned on buying out the prepetition secured obligations. MTS also approached Teva, which declined.
- No third party made a viable proposal. None was interested in a junior facility, and given the size of the secured debt, those contacted were unwilling to enter a priming fight with the prepetition lenders.
- Over several weeks of negotiation, the lenders made these concessions:
- increased the cash available under the facility
- reduced the proposed roll-up
- agreed to in-kind interest on the roll-up
- reduced the original issue discount and the exit fee
- raised the permitted budget variance
- extended the maturity
- The lenders also funded $1.25 million in prepetition bridge financing and consented to the debtors' use of cash collateral.
Prepetition Capital Structure
- At filing, the debtors owed approximately $111.8 million in principal, plus fees, interest, costs and expenses, under an April 19, 2022, credit agreement. BioXcel is the borrower and its two subsidiaries are guarantors. Oaktree Fund Administration, LLC is agent, and the lenders have always been funds affiliated with Oaktree Capital Management and the Qatar Investment Authority.
- The loans are secured by a first-priority perfected lien on substantially all of the debtors' assets. The collateral includes BioXcel's equity in the subsidiaries and the TRANQUILITY lawsuits, with the lien on each lawsuit perfected by a UCC-1 filing.
- Rate: 13% fixed, paid quarterly in cash. BioXcel could elect in-kind interest through June 30, 2025, and some interest was added to principal as a result.
- Exit fee: 0.50% of the principal amount of loans repaid at or before maturity.
- Maturity: April 19, 2027, subject to acceleration after an event of default.
- The credit agreement and a revenue interest financing agreement signed at the same time with the same lender groups originally provided commitments of up to $260 million. In April 2022, BioXcel borrowed $70 million under the initial term loan tranche and received $30 million under the revenue interest agreement.
- In December 2023, ahead of the first minimum revenue covenant test, the lenders pushed the test back to Dec. 31, 2024, and lowered the revenue targets. At the same time, the revenue interest agreement was terminated and exchanged for $30 million in term loans.
- As liquidity tightened, the lenders agreed to further amendments:
- March 2026 (ninth amendment): waived the covenant barring a going-concern qualification in the 2025 audited financial statements and reduced the minimum liquidity covenant to $12.5 million from $15 million, in exchange for a $2.5 million principal prepayment and warrants
- July 2026 (tenth amendment): deferred principal and interest due June 30, 2026, cut minimum liquidity further to $7.5 million, and required BioXcel to enter into a definitive strategic transaction by July 31, 2026
- Aug. 24, 2026: after further amendments, provided $1.25 million in secured bridge financing to finish preparing for the Chapter 11 cases
- The debtors also estimate approximately $17 million in unpaid trade and other ordinary-course obligations, much of it owed to current or former professionals.
Business and Path to Chapter 11
- BioXcel went public in March 2018 and trades on the Nasdaq Capital Market as BTAI. It is a neuroscience biopharmaceutical company built on artificial intelligence, focused on finding new uses for drugs that are already approved or have been tested in clinical trials.
- Its only approved and marketed product is IGALMI (dexmedetomidine) sublingual film. The FDA approved it in April 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, and it is BioXcel's only source of product revenue.
- Substantially all IGALMI sales go through Cardinal Health, which holds finished product on consignment and sells it to wholesalers. Manufacturing is outsourced, in particular to ARx.
- As of Aug. 3, 2026, the neuroscience patent portfolio included 17 issued U.S. utility patents, 13 U.S. utility applications, 29 allowed or granted non-U.S. patents and 41 pending non-U.S. utility applications.
- The sale economics depend on the at-home sNDA. BioXcel announced on Sept. 10, 2025, that its SERENITY at-home Phase 3 trial met its primary objective. It filed the sNDA on Jan. 14, 2026; the FDA accepted it in April 2026 and set a Nov. 14, 2026, target action date.
- After IGALMI launched in July 2022, uptake was slower than expected. BioXcel scaled back its commercial organization, and net IGALMI revenue fell to $0.6 million in 2025 from $2.3 million in 2024, not enough to cover operating expenses, debt service and clinical development costs. The debtors reported a net loss of $27.4 million for the six months ended June 30, 2026.
- Alleged third-party misconduct also compromised the TRANQUILITY Phase 3 trial of BXCL501 in agitation associated with Alzheimer's dementia. BioXcel's June 29, 2023, announcement of positive topline results also disclosed that the FDA had issued a Form 483 at a trial site, which the debtors attribute to a fabricated email that the principal investigator, who was not a BioXcel employee, sent to the FDA. An independent audit BioXcel commissioned found no additional evidence of fraud or data misconduct, and the FDA ultimately concluded that voluntary action was indicated at the site, but the stock fell roughly 64% in a single day and never recovered, which made it much harder for BioXcel to raise equity. The debtors then sued the contract research organization, the company hired to run the trial across multiple sites, and the principal investigator in three separate lawsuits in three jurisdictions.
- In August 2023, the board approved a clinical reprioritization centered on the at-home SERENITY program. It paused or deprioritized TRANQUILITY, BXCL502, the BXCL503 and BXCL504 concepts, and further development of the BXCL701 immuno-oncology program.
- Workforce reductions in May 2024 and September 2024 cut full-time headcount from approximately 60 to 29 by Dec. 31, 2025, and four further departures left 25 at filing. At that point the debtors' only facility was about 18,285 square feet of headquarters office space in New Haven, Conn., leased month to month.
- On July 1, 2026, as part of the tenth amendment, the board replaced its Capital Raise Committee with a Strategic Process Committee. The new committee has exclusive authority over strategic alternatives, including financing, a sale or a Chapter 11 filing. David Mack, a director since November 2024, was initially its only member.
- Susan Atkins joined the board and the Strategic Process Committee on Aug. 12, 2026. The same day, the board formed a Claims Committee, with Atkins as its only member, to investigate and pursue or settle claims against current and former officers and directors and third parties.
- MTS Health Partners, L.P. began marketing the company in fall 2025 to potential strategic buyers and financing partners. Teva emerged as the most viable strategic bidder. After due diligence that included the pending sNDA, Teva submitted a nonbinding letter of intent for a section 363 sale, with its affiliate as stalking horse.
- The board and the Strategic Process Committee concluded that the sale offered more value and a greater chance of closing than raising financing on a standalone basis. They cited tight liquidity, the size of the debt and the need for major lender concessions, uncertain access to capital, and upcoming regulatory milestones that a well-capitalized buyer could pursue.
- BioXcel signed the APA on Aug. 26, 2026, and that day the board and committee decided to file Chapter 11 cases. The debtors filed in Delaware on Aug. 27, 2026.
- The debtors are BioXcel and two Delaware LLC subsidiaries. OnkosXcel Therapeutics, LLC holds the immuno-oncology programs, and OnkosXcel Employee Holdings, LLC is used to grant equity to OnkosXcel service providers. BioXcel had approximately 31 million shares outstanding at filing.
- The debtors' advisers are Cooley LLP and Young Conaway Stargatt & Taylor, LLP as counsel; MTS as investment banker; and MERU, LLC, which provides Chief Restructuring Officer Samir Saleem. Stretto, Inc. is claims and solicitation agent. The court approved a key employee retention program and a key employee incentive program on Sept. 17, 2026.
Liquidation Trust and Reserves
- On the effective date, the debtors pay distributable cash and assign contingent payment rights directly to the DIP agent and/or prepetition agent, without passing them through the trust. All other estate assets vest in the liquidation trust free and clear. These include retained causes of action and the wind-down, professional fee and GUC recovery reserves.
- The trust must dissolve within five years of its creation unless the court approves a fixed-period extension. Beneficial interests in the trust cannot be transferred except by will, intestate succession or operation of law.
- The liquidation trustee will be named in the plan supplement and must be reasonably acceptable to the debtors and both agents. On the effective date, the trustee becomes the only officer, director or manager of each debtor, and the existing officers and directors are deemed to resign.
- The trustee is overseen by consultation parties: the DIP lenders until the DIP claims are paid in full, and the prepetition lenders until their secured and deficiency claims are paid in full. The trustee may settle claims and retained causes of action without court approval.
- The trustee and the trustee's professionals are paid without fee applications, and trustee expenses come out of the wind-down reserve. The trust indemnifies them except for bad faith, willful misconduct (including actual fraud) or gross negligence.
- Wind-down reserve: funded on or before the effective date in an amount reasonably acceptable to both agents. The amount is fixed on the effective date and is not increased or topped up if wind-down costs run higher. Any surplus goes back to the trust for distribution under the plan's priorities.
- Professional fee reserve: funded in an amount acceptable to both agents, or fixed by the court if the amount is disputed. Any amount up to the cumulative professional fees in the approved budget, less amounts already paid, is deemed acceptable. The reserve may be used only for professional fee claims. Any excess goes to the DIP agent until the DIP claims are paid in full, then to the prepetition agent until the prepetition secured claims are paid in full.
- For voting and distribution purposes only, the debtors are treated as consolidated into BioXcel. Guarantees among the debtors are eliminated, and each claim is treated as a single claim against BioXcel. U.S. Trustee fees are still calculated separately for each entity.
Releases, Exculpation and Injunction
- The released parties, each acting in that capacity, are:
- the debtors and their estates
- the debtors' current and former officers, directors, managers and employees
- the post-effective date debtors
- the DIP agent and DIP lenders
- the prepetition agent and prepetition lenders
- the related parties of each of the above
- No one is released to the extent they are named in a retained cause of action. The DIP agent, DIP lenders, prepetition agent, prepetition lenders and the related parties of every released party are released only if they also grant releases.
- The debtors and their estates release the released parties from all claims relating to the debtors, the prepetition loan documents, the cases and the plan, including Chapter 5 claims. Claims arising from criminal acts, willful misconduct, actual fraud or gross negligence, as determined by final order, are excluded.
- The debtor release is subject to the Claims Committee's ongoing investigation. Any exceptions will be identified in the plan supplement.
- The releasing parties are the DIP agent, DIP lenders, prepetition agent and prepetition lenders, plus only those claim holders that vote to accept the plan. Their related parties are included to the extent agency principles would bind them. They give the released parties a matching release with the same exclusions.
- The releases do not affect plan distributions, post-effective date obligations, claims against parties that are not released, or retained causes of action. The release by releasing parties is not given in exchange for any waiver of the debtors' claims, setoffs or defenses against them.
- Exculpation covers the following parties for conduct relating to the cases, the Teva APA and sale, and the plan, through the effective date, excluding actual fraud, willful misconduct and gross negligence:
- the debtors and their estates
- their present and former officers, directors and managers
- the debtors' court-retained professionals
- those parties' related parties, to the extent they are estate fiduciaries
- Equity holders are not exculpated just because they hold equity. After the Claims Committee finishes its investigation, the debtors will identify any parties excluded from exculpation in the plan supplement.
- The plan permanently bars actions against the debtors, their estates and their property on account of claims and interests, and against the released parties on released claims. The SEC keeps its police and regulatory powers and its claims against non-debtors.
- Indemnification claims by directors and officers are payable only from D&O insurance, and those policies survive the effective date. The trustee may pursue claims that are not released and are covered by those policies.
Conditions to the Effective Date
- The effective date requires, among other things:
- a confirmation order that has become final
- closing of the Teva sale under the APA and the sale order
- signing of the liquidation trust agreement, creation of the trust and appointment of the trustee
- funding of the wind-down reserve and the professional fee reserve
- enough cash to pay or reserve for projected allowed administrative, professional fee, priority tax, priority non-tax and other secured claims, U.S. Trustee fees and restructuring expenses
- irrevocable payment in full in cash of all invoiced restructuring expenses
- irrevocable payment in full in cash of the DIP claims, less any administrative shortfall, unless the holders agree to different treatment
- receipt of necessary approvals and consents
- no conversion or dismissal of the cases and no appointment of a trustee or examiner with expanded powers
- The debtors may waive conditions only with the consent of the DIP agent and prepetition agent, not to be unreasonably withheld. If the conditions are not met or waived, the debtors may ask the court to vacate the confirmation order, which would void the plan.
Consent Rights and Plan Modifications
- The confirmation order, solicitation procedures order, plan supplement and liquidation trust agreement must be reasonably acceptable to the DIP agent and prepetition agent. The effective date is set in consultation with them.
- Material changes to the plan, the plan supplement or any exhibit require the consent of the DIP agent and prepetition agent; the plan's cramdown section adds that consent may not be unreasonably withheld, and the introduction also requires the prepetition lenders' consent.
Other Plan Provisions
- Executory contracts and unexpired leases not already assumed, assigned or rejected, and not subject to a pending motion, are rejected on the effective date. The exceptions are contracts entered into after filing in connection with the plan, D&O policies, and contracts listed on the assumption schedule in the plan supplement.
- Rejection damages claims are due 30 days after the earlier of notice of the rejection order and notice of the effective date.
- Requests for payment of administrative claims are due 30 days after the effective date, final professional fee applications 45 days after, and claim objections 180 days after, subject to extension.
- A claim held by a party that is or may be liable on a retained cause of action is treated as disputed and receives no distribution until that liability is settled, withdrawn or determined by final order. Distributions on insured claims wait until the holder exhausts the applicable insurance.
- Distributions on DIP claims, prepetition secured claims and deficiency claims go to the DIP agent or prepetition agent, which pass them on under the respective credit agreements.
- The debtors estimate consolidated federal net operating losses of approximately $510 million to $540 million as of the petition date. The NOL order [Docket No. 114] restricts trading in BioXcel stock and worthless stock deductions by 50% shareholders.
- If the sale order conflicts with the plan, the plan supplement or the confirmation order, the sale order controls.